Not necessarily. If R&D pipeline really is robust, we need time to execute. R&D pre-FDA filing isn't worth more than an FDA filing, which is less than an approved and launched product. R&D formulation lately has been slow to move due to all of the recent product launches, which is the reason to look overseas and start accelerating new product formulation.